Africa

WHO says trials of two Bundibugyo Ebola vaccines to start in Congo next week

Tedros said the Oxford and Moderna candidates will join the Tumaini trial as Congo's deadliest Ebola outbreak passes 5,568 deaths and 11,376 cases.

newsroom@fifthbell.com

November 17, 2026

Congo Ebola vaccine trials begin as deaths mount

Two candidate vaccines against the Bundibugyo strain of Ebola, which is driving the deadliest outbreak in the history of the Democratic Republic of Congo, are expected to enter trials in the outbreak zone next week, the World Health Organization said on Tuesday.

"We expect testing of two candidate vaccines, developed specifically to combat Bundibugyo virus, to begin as soon as possible, perhaps by next week," WHO Director-General Tedros Adhanom Ghebreyesus told a news conference in Geneva.

No vaccine or treatment has been approved for the Bundibugyo strain.

One candidate, ChAdOx1, is an adenoviral vector vaccine developed by the University of Oxford with the Serum Institute of India. The other, mRNA-1469, is a messenger RNA vaccine made by U.S. drugmaker Moderna, Portuguese broadcaster RTP reported.

They are the first vaccines to be included in Tumaini, a WHO-led clinical trial already under way in Congo that tests different approaches in patients with confirmed infections. More than 140 people are enrolled, RTP said.

The outbreak, Congo's 17th, was declared on May 15. It has caused 11,376 cases and 5,568 deaths, according to WHO figures cited by AFP.

Tedros said 400 to 500 new cases are still being recorded each week, and that two-thirds of confirmed deaths occur outside treatment centers.

Congolese health authorities put the fatality rate of the current strain at close to 50%, according to RTP.

Ebola spreads through direct contact with the bodily fluids of an infected person or with contaminated surfaces. Over the past 50 years it has killed more than 15,000 people across Africa, RTP reported.